Information  X 
Enter a valid email address

Smith & Nephew Plc (SN.)

  Print      Mail a friend       Annual reports

Thursday 09 April, 2020

Smith & Nephew Plc

Bob White to join Smith+Nephew's Board as NED

RNS Number : 2916J
Smith & Nephew Plc
09 April 2020
 

 

Medtronic's Bob White joins Smith+Nephew's Board as Non-Executive Director

9 April 2020

 

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce the appointment of Bob White as a Non-Executive Director.

 

Bob is a proven MedTech leader with more than 25 years' experience spanning the US, Europe and Asia Pacific. He is currently Executive Vice President and President, Minimally Invasive Therapies Group and a member of the Executive Committee for Medtronic plc.

 

Bob previously served as Senior Vice President and President of Medtronic Asia Pacific, having led the integration of Covidien Asia Pacific when it was acquired by Medtronic in 2015. At Covidien he served in a number of increasingly senior roles including President, Emerging Markets and President, Respiratory and Monitoring Solutions. He has also held leadership positions at GE Healthcare and IBM.

Bob is a Fellow of the American College of Healthcare Executives. He holds a bachelor's degree in marketing from Cleveland State University and an MBA from Case Western Reserve University. 

Roberto Quarta, Chair of Smith+Nephew, said:

 

"The Board believes it is important that we include a Non-Executive Director with a deep knowledge of the global MedTech space. Bob is a well-regarded and influential member of our industry who brings both large company perspective and the experience of working in the US, our largest market, and Asia Pacific, a vital growth opportunity for Smith+Nephew. We are delighted to have Bob join the Board."

 

Bob will join the Board on 1 May 2020.

 

 

 

-ENDS-

Enquiries

 

Investors


Andrew Swift

+44 (0) 1923 477433

Smith+Nephew




Media


Charles Reynolds

+44 (0) 1923 477314

Smith+Nephew




Susan Gilchrist / Ayesha Bharmal

+44 (0) 20 7404 5959

Brunswick


 

 

About Smith+Nephew

 

Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit  www.smith-nephew.com  and follow us on  Twitter LinkedIn Instagram  or  Facebook .

 

Forward-looking Statements

 

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

 

◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOASSUEFAESSEIL

a d v e r t i s e m e n t